A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.

Authors
Publication date
20 May 2015
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    The University of Manchester - Institutional Repository

    redirect
    oaioai:pure.atira.dk:publications...
    Last time updated on 01/02/2017